Literature DB >> 11248089

Müllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents.

A M Trbovich1, P M Sluss, V M Laurich, F H O'Neill, D T MacLaughlin, P K Donahoe, J Teixeira.   

Abstract

Müllerian Inhibiting Substance (MIS) expression is inversely proportional to the serum concentration of testosterone in males after birth and in vitro studies have shown that MIS can lower testosterone production by Leydig cells. Also, mice overexpressing MIS exhibited Leydig cell hypoplasia and lower levels of serum testosterone, but it is not clear whether this is a result of MIS affecting the development of Leydig cells or their capacity to produce testosterone. To examine the hypothesis that MIS treatment will result in decreased testosterone production by mature Leydig cells in vivo, we treated luteinizing hormone (LH)-stimulated adult male rats and mice with MIS and demonstrated that it can lead to a several-fold reduction in testosterone in serum and in testicular extracts. There was also a slight decrease in 17-OH-progesterone compared to the more significant decrease in testosterone, suggesting that MIS might be regulating the lyase activity of cytochrome P450c17 hydroxylase/lyase (Cyp17), but not its hydroxylase activity. Northern analysis showed that, in both MIS-treated rats and mice, the mRNA for Cyp17, which catalyzes the committed step in androgen synthesis, was down-regulated. In rats, the mRNA for cytochrome P450 side-chain cleavage (P450scc) was also down-regulated by MIS. This was not observed in mice, indicating that there might be species-specific regulation by MIS of the enzymes involved in the testosterone biosynthetic pathway. Our results show that MIS can be used in vivo to lower testosterone production by mature rodent Leydig cells and suggest that MIS-mediated down-regulation of the expression of Cyp17, and perhaps P450scc, contributes to that effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248089      PMCID: PMC30664          DOI: 10.1073/pnas.051632298

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Immunopurified anti-müllerian hormone does not inhibit spontaneous resumption of meiosis in vitro of rat oocytes.

Authors:  A Tsafriri; J Y Picard; N Josso
Journal:  Biol Reprod       Date:  1988-03       Impact factor: 4.285

3.  Müllerian inhibiting substance as oocyte meiosis inhibitor.

Authors:  M Takahashi; S S Koide; P K Donahoe
Journal:  Mol Cell Endocrinol       Date:  1986-10       Impact factor: 4.102

4.  Differential effects of single and repeated administration of gonadotropins on testosterone production and steroidogenic enzymes in Leydig cell populations.

Authors:  P J O'Shaughnessy; A H Payne
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

5.  Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level.

Authors:  J Teixeira; E Fynn-Thompson; A H Payne; P K Donahoe
Journal:  Endocrinology       Date:  1999-10       Impact factor: 4.736

6.  Adenosine 3',5'-monophosphate-mediated induction of 17 alpha-hydroxylase and C 17-20 lyase activities in cultured mouse Leydig cells is enhanced by inhibition of steroid biosynthesis.

Authors:  C S Rani; A H Payne
Journal:  Endocrinology       Date:  1986-03       Impact factor: 4.736

7.  Characterization of several clonal lines of cultured Leydig tumor cells: gonadotropin receptors and steroidogenic responses.

Authors:  M Ascoli
Journal:  Endocrinology       Date:  1981-01       Impact factor: 4.736

8.  Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.

Authors:  P T Ma; G Gil; T C Südhof; D W Bilheimer; J L Goldstein; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

9.  Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro.

Authors:  S Ueno; T F Manganaro; P K Donahoe
Journal:  Endocrinology       Date:  1988-09       Impact factor: 4.736

10.  Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells.

Authors:  R L Cate; R J Mattaliano; C Hession; R Tizard; N M Farber; A Cheung; E G Ninfa; A Z Frey; D J Gash; E P Chow
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

View more
  18 in total

1.  Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.

Authors:  Henry L Chang; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Xianlin Li; Xiaolong Wei; David T MacLaughlin; Patricia K Donahoe
Journal:  Gynecol Oncol       Date:  2010-11-06       Impact factor: 5.482

Review 2.  Emerging Roles of Anti-Müllerian Hormone in Hypothalamic-Pituitary Function.

Authors:  Anne-Laure Barbotin; Maëliss Peigné; Samuel Andrew Malone; Paolo Giacobini
Journal:  Neuroendocrinology       Date:  2019-07-05       Impact factor: 4.914

Review 3.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

4.  Functional Genetic Variation in the Anti-Müllerian Hormone Pathway in Women With Polycystic Ovary Syndrome.

Authors:  Lidija K Gorsic; Matthew Dapas; Richard S Legro; M Geoffrey Hayes; Margrit Urbanek
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

5.  Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.

Authors:  Dorry L Segev; Yasunori Hoshiya; Makiko Hoshiya; Trinh T Tran; Jennifer L Carey; Antonia E Stephen; David T MacLaughlin; Patricia K Donahoe; Shyamala Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

6.  Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women's Interagency HIV Study.

Authors:  Zaher O Merhi; David B Seifer; Jeremy Weedon; Oluwatoyin Adeyemi; Susan Holman; Kathryn Anastos; Elizabeth T Golub; Mary Young; Roksana Karim; Ruth Greenblatt; Howard Minkoff
Journal:  Fertil Steril       Date:  2012-04-10       Impact factor: 7.329

7.  Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Authors:  Rafael Pieretti-Vanmarcke; Patricia K Donahoe; Lisa A Pearsall; Daniela M Dinulescu; Denise C Connolly; Elkan F Halpern; Michael V Seiden; David T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

8.  Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells.

Authors:  Peter J Malloy; Lihong Peng; Jining Wang; David Feldman
Journal:  Endocrinology       Date:  2008-12-04       Impact factor: 4.736

9.  Expression of MIS in the testis is downregulated by tumor necrosis factor alpha through the negative regulation of SF-1 transactivation by NF-kappa B.

Authors:  Cheol Yi Hong; Jin Hee Park; Kook Heon Seo; Jin-Man Kim; Suhn Young Im; Jae Woon Lee; Hueng-Sik Choi; Keesook Lee
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

10.  Regulation of gonadotropin gene expression by Mullerian inhibiting substance.

Authors:  Grégoy Y Bédécarrats; Francis H O'Neill; Errol R Norwitz; Ursula B Kaiser; Jose Teixeira
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.